What dose of aztreonam combined with avibactam (as ceftazidime‑avibactam) should be administered to a 75‑year‑old patient with a carbapenem‑resistant Escherichia coli urinary infection, including adjustments for different levels of renal function?

Dosing of Aztreonam-Avibactam Combination for Carbapenem-Resistant E. coli UTI

For a 75-year-old patient with carbapenem-resistant E. coli urinary infection, administer aztreonam 2 grams IV every 6-8 hours combined with ceftazidime-avibactam 2.5 grams IV every 8 hours, with both agents infused simultaneously over 2-3 hours, adjusting doses based on renal function.

Standard Dosing Regimen

The combination therapy consists of two components administered concurrently:

Ceftazidime-Avibactam Component:

• Standard dose: 2.5 grams (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours 1
• Infusion duration: 2-3 hours (prolonged infusion recommended for high MIC pathogens) 1

Aztreonam Component:

• Standard dose: 2 grams IV every 6-8 hours 2, 3
• Infusion duration: 2 hours or continuous infusion 3
• Total daily dose: 6-8 grams/day 3

Critical Dosing Principles

Simultaneous administration is essential - staggered dosing (giving ceftazidime-avibactam first, then aztreonam) results in inferior bacterial killing and should be avoided 3. Both agents must be infused at the same time to achieve optimal synergy.

Prolonged infusion enhances efficacy - extending infusion duration to 2-3 hours significantly improves bacterial eradication compared to standard 30-minute infusions, particularly for organisms with elevated MICs 1, 3. This approach maximizes time above MIC, which is critical for β-lactam pharmacodynamics.

Renal Dose Adjustments

For Ceftazidime-Avibactam:

CrCl 31-50 mL/min:

• 1.25 grams IV every 8 hours

CrCl 16-30 mL/min:

• 0.94 grams IV every 12 hours

CrCl 6-15 mL/min:

• 0.94 grams IV every 24 hours
• Note: Suboptimal target attainment (≤71%) predicted at this level 2

CrCl <5 mL/min or hemodialysis:

• Consult infectious disease specialist for individualized dosing

For Aztreonam:

CrCl 10-30 mL/min:

• Initial dose: 1-2 grams
• Maintenance: 50% of usual dose at usual intervals

CrCl <10 mL/min:

• Initial dose: 1-2 grams
• Maintenance: 25% of usual dose at usual intervals 4

Hemodialysis patients:

• Supplemental dose of 12.5% (1/8) of initial dose after each dialysis session 4

Treatment Duration

For complicated UTI (including pyelonephritis): 5-7 days 1

The guidelines consistently recommend shorter courses for urinary tract infections compared to bloodstream infections (7-14 days) or pneumonia (10-14 days) 1.

Important Clinical Considerations

Infectious disease consultation is strongly recommended for all multidrug-resistant organism infections 1. This combination represents advanced therapy for highly resistant pathogens.

Susceptibility testing is critical - while this combination shows synergy in 75-95% of carbapenem-resistant Enterobacterales 5, 6, 7, approximately 18% of isolates may demonstrate aztreonam MIC ≥4 μg/mL even when combined with avibactam 6. In vitro testing should guide therapy when possible.

Monitor for resistance emergence - ceftazidime-avibactam resistance can develop during therapy, particularly in KPC-producing organisms 1. Some experts recommend adding a carbapenem or colistin to ceftazidime-avibactam when treating KPC-3 producers, though this is not specifically addressed for the aztreonam combination in urinary infections.

Neurological monitoring - both aztreonam and ceftazidime can cause neurological adverse effects including encephalopathy, myoclonus, and seizures, particularly in patients with renal impairment 8. Dose adjustment is essential in elderly patients with declining renal function.

Practical Implementation

For a 75-year-old patient, calculate creatinine clearance using CKD-EPI equation rather than relying solely on serum creatinine, as this better predicts drug clearance in elderly patients 2. Age-related decline in renal function is common and may not be reflected in serum creatinine alone.

Start both agents simultaneously as separate infusions over 2-3 hours every 8 hours for ceftazidime-avibactam, with aztreonam dosed every 6-8 hours depending on severity and renal function 3. The 8-gram daily aztreonam regimen (2 g every 6 hours) showed superior bacterial killing in hollow-fiber models but requires careful renal monitoring 3.

This combination specifically addresses metallo-β-lactamase producers (like NDM) that are resistant to ceftazidime-avibactam alone, as aztreonam is not hydrolyzed by metallo-β-lactamases while avibactam protects aztreonam from other β-lactamases 5, 9.